Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms (APHYPAP)

NCT03808805 PHASE3 COMPLETED

Phase 3, randomized prospective study, double blind-double placebo, testing oral therapies APREPITANT versus HYDROXYZINE in patients followed for myeloproliferative neoplasms and suffering of persistent aquagenic pruritus.

Details

Lead sponsor	University Hospital, Brest
Phase	PHASE3
Status	COMPLETED
Enrolment	63
Start date	Tue Apr 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Aug 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Myeloproliferative Disorder
• Aquagenic Pruritus

Interventions

• Aprepitant 80 mg
• Hydroxyzine 25mg
• Placebo of Hydroxyzine
• Placebo of Aprepitant

Countries

France